TNF and lymphoma: However, the long-term use of Infliximab increases the risk for the reactivation of tuberculosis and the possible development of lymphoma and indicates the use of new biologics which should suppress TNF-α-driven inflammation in IOIS patients without causing life-threatening systemic immunosuppression [45].